Proliferating tumor and normal cells

Proliferating tumor and normal cells refer to a physiological state of active cell division rather than a specific molecular target or receptor. In the context of oncology, this population is the primary focus of traditional cytotoxic chemotherapy, which exploits the rapid growth of malignant cells (National Cancer Institute, 2023). These therapies typically interfere with essential cellular processes such as DNA replication, nucleotide synthesis, or microtubule assembly during mitosis (StatPearls, 2023). Because these processes are fundamental to all dividing cells, the drugs cannot distinguish between cancerous cells and healthy, rapidly dividing tissues. This lack of specificity leads to damage in the bone marrow, gastrointestinal tract, and hair follicles, resulting in common side effects like myelosuppression and mucositis (American Cancer Society, 2024). Biomarkers such as Ki-67 and Proliferating Cell Nuclear Antigen (PCNA) are frequently used to quantify the proportion of cells in this state within a tissue sample (PubMed, 2022). While historically significant, modern drug development has shifted away from targeting proliferation broadly toward targeting specific molecular drivers to improve the therapeutic index.

Other names

Dividing cellsCycling cellsMitotic cellsHyperproliferative cells

Inhibition of DNA synthesis, induction of DNA damage, or disruption of mitotic spindle assembly in cells undergoing division.